Drug intelligence / Profile preview

CGT-8012

Development stage: Unknown
Lead developer: CGeneTech
Modality: Small Molecules
Administration: Oral

Overview

CGT-8012 is a **Dipeptidyl peptidase-4 inhibitor** being developed and marketed by **CGeneTech** for **diabetes**. Based on the company pipeline information provided, it is an **approved** product targeting **DPP4**, consistent with an incretin-enhancing mechanism intended to improve glycemic control by preventing degradation of endogenous incretin hormones such as GLP-1 and GIP. No specific brand name, active ingredient identity beyond the code, dosage form, route, or modality details were explicitly provided in the supplied source material.

Targets

DPP-4 (Dipeptidyl Peptidase-IV)CYP2D6 (Cytochrome P450 2D6)

Beyond the preview

Go deeper on CGT-8012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGT-8012.

Explore the full profile